Given the dramatic hyper-resistance seen in p110δD910A mice infected with L. donovani and L. major[26], we speculate that the use of highly specific pharmacological inhibitors of p110δ may be beneficial in the treatment of human cutaneous and visceral leishmaniasis. This evidence concerns the gene PIK3CD and visceral leishmaniasis.